Das Oncocare Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 11.07%
- Profit Growth -15.70%
- Ebitda -33.62%
- Net Worth -83.98%
- Total Assets -55.20%
About Das Oncocare
Das Oncocare Private Limited (DOPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 September 2018 (Six years and five months 16 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Bandita Patro, Netajee Patro, Kiran Das, and One other member serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999MH2018PTC313929
- Company No.
313929
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Sep 2018
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Das Oncocare?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Das  | Director | 12-Sep-2018 | Current |
Bandita Patro  | Director | 12-Sep-2018 | Current |
| Netajee Patro | Director | 22-Jul-2022 | Current |
| Jasmine Das | Director | 12-Sep-2018 | Current |
Financial Performance of Das Oncocare.
Das Oncocare Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.07% increase. The company also saw a substantial fall in profitability, with a 15.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 83.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Das Oncocare?
In 2022, Das Oncocare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mundial Pharmaceuticals Private LimitedBandita Patro is a mutual person
Zetechno Products And Services Private LimitedKiran Das is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Das Oncocare?
Unlock and access historical data on people associated with Das Oncocare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Das Oncocare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Das Oncocare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.